Traws Pharma (NASDAQ:TRAW) Raised to Sell at Wall Street Zen

Traws Pharma (NASDAQ:TRAW) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday.

Several other equities analysts have also recently issued reports on TRAW. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Traws Pharma in a research report on Wednesday, May 20th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Traws Pharma Price Performance

Traws Pharma stock opened at $1.28 on Friday. Traws Pharma has a 1-year low of $1.00 and a 1-year high of $3.27. The stock has a market cap of $13.00 million, a PE ratio of -0.76 and a beta of 1.45. The stock’s fifty day moving average is $1.49 and its two-hundred day moving average is $1.75.

Traws Pharma (NASDAQ:TRAW) last posted its earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. On average, research analysts expect that Traws Pharma will post -2.23 earnings per share for the current fiscal year.

Insider Buying and Selling at Traws Pharma

In related news, major shareholder Orbimed Advisors Llc bought 597,729 shares of Traws Pharma stock in a transaction that occurred on Thursday, April 16th. The shares were purchased at an average price of $1.67 per share, with a total value of $998,207.43. Following the purchase, the insider owned 1,203,250 shares in the company, valued at $2,009,427.50. This represents a 98.71% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 7.57% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TRAW. Squadron Capital Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth $806,000. Ikarian Capital LLC lifted its stake in shares of Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares during the period. Adage Capital Partners GP L.L.C. lifted its stake in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares during the period. Boothbay Fund Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth $220,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Traws Pharma during the 4th quarter worth $175,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.